Medical Technology & Innovations, Inc.
From Academic Research to Commercial Medical Technology
Medical Technology & Innovations, Inc. (MTI) was founded by Jeremy P. Feakins to commercialize pioneering academic research into the early detection of serious vision disorders in infants, preverbal children and other patients who could not reliably participate in conventional vision screening.
The underlying research was developed by Dr. Howard Freedman, whose work demonstrated the potential of photographic screening techniques to identify abnormalities that might otherwise remain undetected during the critical early years of visual development.
Jeremy recognized that the research had the potential to become a practical medical screening technology and established MTI to take the concept from the academic environment into commercial use.
Developing the PhotoScreener
MTI developed the research into the PhotoScreener, a microprocessor-based medical device designed to help identify children at risk of serious eye disorders before those conditions could cause permanent visual impairment.
Bringing the technology to market required considerably more than developing the original concept. MTI transformed the research into a manufacturable finished product, developed the necessary electronics, software and operating systems, completed product development and testing, navigated the regulatory process, established manufacturing and distribution capabilities, and introduced the finished device to the healthcare market.
The PhotoScreener ultimately received FDA clearance and was distributed as a commercial medical device.
Financing the Company and Going Public
As MTI developed, Jeremy was responsible for building the company and securing the capital required to move the technology from research through product development and commercialization.
In 1996, he led MTI through a transaction that made the company publicly traded in the United States.
Becoming a public company provided MTI with access to the capital markets as the business moved from product development into commercialization and gave Jeremy first-hand experience in virtually every aspect of building and financing an emerging public company—from private capital formation and securities transactions to investor relations, corporate governance and the continuing responsibilities of managing a publicly traded business.
Strategic Sale of the Technology
Following commercialization of the PhotoScreener, the technology rights were ultimately sold to a major international eyewear company, completing the journey from academic research to a developed, regulated and commercially distributed medical technology.
For Jeremy, the MTI experience became an important foundation for the work he has undertaken during the decades since.
It demonstrated the entire entrepreneurial cycle:
Identify promising technology. Develop the commercial opportunity. Build the company. Raise the capital. Navigate regulation. Bring the product to market. Access the public markets. Create strategic value. Complete the transaction.
That experience continues to shape JPF Venture Group's approach today: helping entrepreneurs and management teams think beyond the immediate financing requirement and focus instead on building companies capable of creating lasting enterprise value.
Important Information
JPF Venture Group provides strategic and capital-markets advisory services on a fee-for-service basis. JPF Venture Group is not a registered broker-dealer and does not receive commissions or other transaction-based compensation based upon the amount of capital raised.
JPF Venture Group does not guarantee that financing will be available or that any financing or strategic transaction will be completed. Where regulated securities activities are required, such activities must be conducted through appropriately registered or exempt persons or entities.
Information provided on this website is for general informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.
Submission of information through this website does not create an advisory, fiduciary, brokerage or other professional relationship.
JPF Venture Group, Inc.
Lancaster, Pennsylvania, USA
Phone: +1 717 715 0238
Email: jpf@jpfvg.com
Mailing Address: 128 East Grant Street, Suite 103 Lancaster, Pennsylvania, USA